AbbVie reports positive Phase 3 atogepant results in menstrual migraine
Atogepant met the primary and all eight ranked secondary endpoints in the Phase 3 Luna study, according to the report.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.